Individuals with diabetes are inherently at a higher risk of further cardiovascular events particularly in the context of an ACS, and additional dedicated studies would be needed to evaluate benefits versus the risks from early initiation of SGLT2 inhibition in those with T2DM especially in the setting of acute coronary syndromes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.